Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Eli Lilly and Company
AstraZeneca
National Institutes of Health Clinical Center (CC)
Pfizer
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Amgen
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exscientia AI Limited
Seagen Inc.
Conjupro Biotherapeutics, Inc.
Boehringer Ingelheim
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Moonlight Bio, Inc
Boehringer Ingelheim
Debiopharm International SA
Sotio Biotech Inc.
Novartis
National Cancer Institute (NCI)
Avacta Life Sciences Ltd
University Health Network, Toronto
BeOne Medicines
University of Chicago
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Abdera Therapeutics Inc.
University of Maryland, Baltimore
NiKang Therapeutics, Inc.
MacroGenics
Amgen
SystImmune Inc.
SN BioScience
Boundless Bio, Inc.
Centre Antoine Lacassagne
SciTech Development, Inc.
AbbVie
Amgen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Amgen
Nerviano Medical Sciences
Boehringer Ingelheim
AbbVie
Incyte Corporation
Amgen
Janux Therapeutics
Novartis